Investing.comCodex · 实盘不做把握 7/10
北京时间·🕒 发布 18:36:33时区推断·⟳ 抓取 18:37:12·⚡ 决策 07-29 18:49:10 +11m58s·90.1 天前
United Therapeutics的PAH药物ralinepag三期结果获Lancet发表，但核心疗效数据早在3月已披露
当前Lancet发表确认ralinepag三期ADVANCE OUTCOMES数据，55%降低临床恶化风险、无新增安全信号，对长期管线价值偏正面。
📄 原文Investing.com↗ 原文
United Therapeutics’ ralinepag meets primary endpoint in phase 3 trial
S. Korea’s KOSPI rebounds to close 6% in red; SK Hynix drops 10% SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - Un…
不做 United Therapeutics（UTHR.US）
不做：ralinepag三期55%降低临床恶化风险是3月已披露、5月ATS已展示的旧核心数据，今天只是论文/媒体再传播，未形成新的可交易临床或监管节点。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司首次宣布ADVANCE OUTCOMES达到主要终点，ralinepag降低临床恶化风险55%，并计划提交NDA。
- 公司在ATS展示完整结果，重复披露HR 0.45、NT-proBNP和6MWD改善、无新增安全信号。
- 会议摘要已发表相同疗效与安全性数据，说明数据在学术渠道也已传播。
- Investing.com报道Lancet发表结果，但正文核心数字与3月、5月已披露信息一致。市场反应:UTHR盘前最新价523.63美元，较前收-0.82%，未见同向重定价。
关键理由
- 当前Lancet发表确认ralinepag三期ADVANCE OUTCOMES数据，55%降低临床恶化风险、无新增安全信号，对长期管线价值偏正面。
- 但核心疗效数据、ATS全文展示和NDA计划分别已在2026-03-02、2026-05-17和公司一季报中公开，今天不是新的临床读出或监管获批。
- 量级上，竞品Uptravi 2025年全球销售约19亿美元、美国约15亿美元，ralinepag若获批有商业潜力，但这次仅是论文发表，不能直接改变短线收入或获批概率。
主要风险
- 论文发表不是FDA批准，ralinepag仍为未获批药物，真正可交易节点更可能是NDA受理、PDUFA或标签结果。
- UTHR盘前最新价523.63美元、较前收-0.82%，市场未对这条旧数据再定价。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-07-29 · 影响 none
内部KB未命中改变方向的新鲜增量，未发现今天之前未披露的额外商业或监管进展。
检索:United Therapeutics ralinepag ADVANCE OUTCOMES primary endpoint NDA June 2026 PAH - 做多前查反向 · 来源 web · 日期 2026-03-02 · 影响 invalidates
Web核实核心三期数据早已由公司首发，削弱将今日报道作为可交易新催化的理由。
检索:United Therapeutics ralinepag ADVANCE OUTCOMES met primary endpoint announced September 2024 NDA June 2026 PAH 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,061 字
S. Korea’s KOSPI rebounds to close 6% in red; SK Hynix drops 10%
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Therapeutics Corporation (NASDAQ:UTHR) announced today that The Lancet published results from its phase 3 ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension treatment.
The study met its primary endpoint, showing ralinepag reduced the risk of a clinical worsening event by 55% compared with placebo in patients with PAH, according to a press release statement. The hazard ratio was 0.45 with a 95% confidence interval of 0.33-0.62 and p-value less than 0.0001.
The trial enrolled 687 patients with PAH, with 80% on dual background therapy and 70% classified as World Health Organization Functional Class II at baseline. Patients received either ralinepag or placebo in addition to standard care, with once-daily dosing individualized based on tolerability and clinical response.
Ralinepag achieved statistically significant improvements from baseline to week 28 in two key secondary endpoints. The drug showed a 24.3% reduction in N-terminal pro-B-type natriuretic peptide over placebo and a 20.4-meter placebo-corrected difference in six-minute walk distance. Ralinepag increased the odds of achieving clinical improvement by 47% compared to placebo.
The most commonly reported adverse events in the ralinepag group were headache, diarrhea, nausea, and myalgia. The adverse event profile was consistent with known prostacyclin pathway effects, and no new safety signals were observed.
Ralinepag is an oral prostacyclin receptor agonist designed for once-daily administration. United Therapeutics submitted a New Drug Application for ralinepag to the U.S. Food and Drug Administration in June 2026. The drug has not been approved for use in any indication and remains investigational for PAH.
PAH affects approximately 500,000 individuals worldwide, with around 50,000 people affected in the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Therapeutics Corporation (NASDAQ:UTHR) announced today that The Lancet published results from its phase 3 ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension treatment.
The study met its primary endpoint, showing ralinepag reduced the risk of a clinical worsening event by 55% compared with placebo in patients with PAH, according to a press release statement. The hazard ratio was 0.45 with a 95% confidence interval of 0.33-0.62 and p-value less than 0.0001.
The trial enrolled 687 patients with PAH, with 80% on dual background therapy and 70% classified as World Health Organization Functional Class II at baseline. Patients received either ralinepag or placebo in addition to standard care, with once-daily dosing individualized based on tolerability and clinical response.
Ralinepag achieved statistically significant improvements from baseline to week 28 in two key secondary endpoints. The drug showed a 24.3% reduction in N-terminal pro-B-type natriuretic peptide over placebo and a 20.4-meter placebo-corrected difference in six-minute walk distance. Ralinepag increased the odds of achieving clinical improvement by 47% compared to placebo.
The most commonly reported adverse events in the ralinepag group were headache, diarrhea, nausea, and myalgia. The adverse event profile was consistent with known prostacyclin pathway effects, and no new safety signals were observed.
Ralinepag is an oral prostacyclin receptor agonist designed for once-daily administration. United Therapeutics submitted a New Drug Application for ralinepag to the U.S. Food and Drug Administration in June 2026. The drug has not been approved for use in any indication and remains investigational for PAH.
PAH affects approximately 500,000 individuals worldwide, with around 50,000 people affected in the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。